Response to Letter Regarding Article, “Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms”
Author(s) -
Shirya Rashid,
Hagai Tavori,
Patrick Brown,
MacRae F. Linton,
Jane He,
Ilaria Giunzioni,
Sergio Fazio
Publication year - 2015
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.114.013729
Subject(s) - kexin , proprotein convertase , medicine , subtilisin , apolipoprotein b , pcsk9 , overproduction , triglyceride , endocrinology , lipoprotein , ldl receptor , biochemistry , cholesterol , enzyme , biology
In our Circulation article,1 we stated that few studies have addressed the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the small intestine and in the metabolism of triglyceride-rich lipoproteins. In their letter, Drs Le May and Cariou point out the omission of 2 references. The first, published by Le May et al2 in 2009, reports that PCSK9−/− mice display reduced postprandial hypertriglyceridemia and apolipoprotein B levels after olive oil gavage and that adenoviral PCSK9 overexpression or targeted shRNA silencing of PCSK9 increased and reduced apolipoprotein B secretion, respectively. In that article, Le May et al2 acknowledge an earlier observation, published by 1 of us (S.R.) in 2005, that apolipoprotein B48 levels are reduced …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom